Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Status
Recruiting
Condition
Lymphoma, Non-Hodgkin
Phase
Phase 1
INTERVENTION
Drug: CC-95775
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study :
All
Accepts Healthy Volunteers :
Result 1 of 2
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies